
Shire has followed up its marketing applications for Gaucher disease treatment velaglucerase alfa in the US and Canada with a …
Shire has filed for early US approval of its Gaucher disease drug velaglucerase alfa, as supplies to Genzyme's established rival …
Shire Pharmaceuticals is shutting down a US production facility and will outsource the production to contract manufacturers DSM.The measure is …
Shire has withdrawn the European marketing application for its Attention Deficit Hyperactivity Disorder (ADHD) patch product Daytrana. The product's active …
Shire has bought the global rights for two established treatments for Attention Deficit Hyperactivity Disorder from UCB. The acquisition gives …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

